Production (Stage)
Bright Minds Biosciences Inc.
DRUG
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -382.70% | 102.86% | 51.77% | 113.85% | 71.91% |
| Total Depreciation and Amortization | 17.16% | 15.79% | 2.96% | -2.22% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 160.83% | -632.29% | -69.90% | 49.22% | 471.00% |
| Change in Net Operating Assets | 72.87% | -119.87% | 135.98% | 53.23% | -200.48% |
| Cash from Operations | -182.97% | -76.67% | 61.96% | 114.28% | 46.60% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -11.82% | -8.18% | -10.65% | -2.33% | -2.33% |
| Issuance of Common Stock | -- | 5,406.57% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,063.19% | 5,660.24% | -7.45% | 0.00% | -2.52% |
| Foreign Exchange rate Adjustments | -631.25% | 3,844.37% | 110.01% | -70.24% | 58.97% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -151.15% | 372,635.00% | 66.56% | 116.42% | 45.96% |